Tomorrow at the Newseum, The Hill will be hosting a live discussion about the transition from volume-based to value-based care. A live webcast will be available for the event, which begins at 8:30 am ET.
Last week, Jim Robinson, President of Astellas Pharma US, shared his thoughts in a related op-ed at The Hill.
Biopharmaceutical innovation is transforming what it means to be a patient battling some of our most difficult diseases, such as cancer, HIV/AIDS, diabetes and cardiovascular disease. New medicines are not only saving and extending lives, but doing so with better safety profiles that improve quality of life.
But are we capturing these benefits in the ways we measure the value of medicines – and in the decisions that inform access to these therapies?
Since the Medicare Prescription Drug Improvement and Modernization Act of 2003, the Centers for Medicare and Medicaid Services has put in place myriad quality reporting and performance programs – and recently HHS set a goal of tying 85 percent of all traditional Medicare payments to quality or value by 2016 and 90 percent by 2018.
However, a key hurdle in this transformation is the development of credible, patient-focused quality measurements centered on real outcomes.
Read the full piece here.
Featured speakers for the Newseum event include:
Rep. Michael Burgess (R-TX-26)
Marc Boutin, CEO, National Health Council
Dr. Christine Cassel, President & CEO, National Quality Forum
Dr. Patrick Conway, Acting CMS Principal Deputy Administrator, Deputy Administrator for Innovation and Quality, and CMS Chief Medical Officer
Dr. Barbara Hutchinson, President-Elect, Association of Black Cardiologists
Elizabeth Jurinka, Minority Chief Health Policy Advisor, Senate Finance Committee
Jim Robinson, President, Astellas Pharma US
Dr. Janet Wright, Executive Director, Million Hearts